Inflammatory Bowel Disease
Conditions
Brief summary
A thorough discussion of treatment options to manage inflammatory bowel disease (IBD), including the risks and benefits of each class of medication, can be a complex discussion and time consuming. Having to use a translator adds an additional layer of time and complexity to these discussions as well as potential misunderstanding. Further, in addition to language, cultural differences can also play into treatment acceptance. This study aims to determine the impact of primary language on the selection of treatment for IBD and on disease outcomes.
Interventions
OTHERNO INTERVENTION
NO INTERVENTION - OBSERVATIONAL ONLY
Sponsors
Bristol-Myers Squibb
Yale University
University of Texas at Austin
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥18 years of age * Confirmed diagnosis of IBD (CD, UC or indeterminate colitis) * Willing to provide consent for participation * Managed at an outpatient clinic either the Yale New Haven Hospital system or the University of Texas at Austin Hospital system.
Exclusion criteria
* Patients \<18 * No confirmed diagnosis of IBD * Not planning to continue care at either study site (i.e. presenting for a consultation only) * Unwilling to provide signed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Current use of advanced therapy | baseline | Use of or prescription of a biologic or small molecule therapy to treat inflammatory bowel disease |
Secondary
| Measure | Time frame |
|---|---|
| IBD-related disease complications | 6 months |
Countries
United States
Contacts
Primary ContactLinda A Feagins, MD
Outcome results
None listed